Country: United States
Language: English
Source: NLM (National Library of Medicine)
CANGRELOR (UNII: 6AQ1Y404U7) (CANGRELOR - UNII:6AQ1Y404U7)
The Medicines Company
CANGRELOR
CANGRELOR 50 mg
INTRAVENOUS
PRESCRIPTION DRUG
KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. KENGREAL is contraindicated in patients with significant active bleeding [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . KENGREAL is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to KENGREAL or any component of the product [see Adverse Reactions ( 6.1 )] . Pregnancy Category C There are no adequate and well-controlled studies of KENGREAL in pregnant women. Cangrelor did not produce malformations in either the rat or rabbit reproductive studies, and is not considered to be a teratogen. In embryo-fetal development studies in rats, cangrelor produced dose-related fetal growth retardation characteri
KENGREAL is supplied as a sterile lyophilized powder in single-use 10 mL vials. Vials of KENGREAL should be stored at USP Controlled Room Temperature, [20°C to 25°C (68°F to 77°F) with excursions between 15°C and 30°C (59°F and 86°F) permitted]. Distributed by: The Medicines Company Parsippany, NJ 07054 PN 1924-2
New Drug Application
KENGREAL- CANGRELOR INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION THE MEDICINES COMPANY ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE KENGREAL SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR KENGREAL. KENGREAL (CANGRELOR) FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2015 INDICATIONS AND USAGE KENGREAL is a P2Y platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. (1) DOSAGE AND ADMINISTRATION KENGREAL is intended for administration via a dedicated IV line, only after reconstitution and dilution. (2.3) Administer 30 mcg/kg intravenous (IV) bolus prior to PCI followed immediately by a 4 mcg/kg/min IV infusion for at least 2 hours or duration of procedure, whichever is longer. (2.1) To maintain platelet inhibition after discontinuation of KENGREAL infusion, an oral P2Y platelet inhibitor should be administered. (2.2) DOSAGE FORMS AND STRENGTHS Single-use 10 mL vial containing 50 mg KENGREAL as a lyophilized powder for reconstitution (3.0) CONTRAINDICATIONS Significant active bleeding (4.1) Hypersensitivity to KENGREAL or any component of the product (4.2) WARNINGS AND PRECAUTIONS Bleeding: Like other drugs that inhibit platelet P2Y function, KENGREAL can increase the risk of bleeding (5.1) ADVERSE REACTIONS The most common adverse reaction is bleeding. (5.1, 6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT THE MEDICINES COMPANY AT 1-888-977-6326 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Clopidogrel: Do not administer during KENGREAL infusion. (7.1) Prasugrel: Do not administer during KENGREAL infusion. (7.1) REVISED: 8/2016 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTR Read the complete document